A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies (Q79382565)

From Wikidata

Jump to navigation Jump to search

scientific article published on 28 November 2006

Language	Label	Description	Also known as
English	A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies	scientific article published on 28 November 2006

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17126894%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17126894%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

phase II clinical trial

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17126894%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

author name string

M V Seiden

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17126894%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

H A Burris

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17126894%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

U Matulonis

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17126894%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

J B Hall

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17126894%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

D K Armstrong

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17126894%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

J Speyer

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17126894%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

J D A Weber

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17126894%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

publication date

28 November 2006

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17126894%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

Gynecologic Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17126894%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

104

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17126894%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

727-731

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17126894%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17126894%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.10.019

7 January 2021

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.10.019

7 January 2021

Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.10.019

7 January 2021

Cancer of the ovary

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.10.019

7 January 2021

A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.10.019

7 January 2021

Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.10.019

7 January 2021

Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.10.019

7 January 2021

Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.10.019

7 January 2021

Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.10.019

7 January 2021

Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.10.019

7 January 2021

Rationale and clinical experience with epidermal growth factor receptor inhibitors in gynecologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.10.019

7 January 2021

EGFR signal transactivation in cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.10.019

7 January 2021

EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.10.019

7 January 2021

Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.10.019

7 January 2021

A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.10.019

7 January 2021

Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group)

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.10.019

7 January 2021

Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.10.019

7 January 2021

The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.10.019

7 January 2021

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.10.019

7 January 2021

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.10.019

7 January 2021

Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.10.019

7 January 2021

Efficacy and safety of trastuzumab as a single agent in heavily pretreated patients with HER-2/neu-overexpressing metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.10.019

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.10.019

7 January 2021

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.10.019

7 January 2021

Cetuximab: in the treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.10.019

7 January 2021

Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.10.019

7 January 2021

Phase II trial of anastrozole in women with asymptomatic müllerian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.10.019

7 January 2021

Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.10.019

7 January 2021

EGFR mutation and response of lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.10.019

7 January 2021

Response to gefitinib in bronchioloalveolar carcinoma in the absence of EGFR mutation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.10.019

7 January 2021

Predictors of the response to gefitinib in refractory non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.10.019

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.10.019

7 January 2021

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.10.019

7 January 2021

Modeling resistance to pathway-targeted therapy in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.10.019

7 January 2021

Identifiers

10.1016/J.YGYNO.2006.10.019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17126894%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17126894%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q79382565&oldid=1647948703"